Publication:
Correlation between levofloxacin consumption and the incidence of nosocomial infections due to fluoroquinolone-resistant Escherichia coli

cris.lastimport.scopus2025-05-08T22:03:38Z
cris.virtual.departmentLaboratory Medicineen_US
cris.virtual.departmentLaboratory Medicine-NTUHen_US
cris.virtual.orcid0000-0002-7502-9225en_US
cris.virtualsource.departmentd73d2aff-b7b3-4ae4-8463-9e4b852cb568
cris.virtualsource.departmentd73d2aff-b7b3-4ae4-8463-9e4b852cb568
cris.virtualsource.orcidd73d2aff-b7b3-4ae4-8463-9e4b852cb568
dc.contributor.authorWu H.-H.en_US
dc.contributor.authorLiu H.-Y.en_US
dc.contributor.authorLin Y.-C.en_US
dc.contributor.authorPO-REN HSUEHen_US
dc.contributor.authorLee Y.-J.en_US
dc.creatorWu H.-H.;Liu H.-Y.;Lin Y.-C.;Po-Ren Hsueh;Lee Y.-J.
dc.date.accessioned2020-12-18T08:37:24Z
dc.date.available2020-12-18T08:37:24Z
dc.date.issued2016
dc.description.abstractBackground/purpose The relationship between fluoroquinolone resistance in Escherichia coli isolates causing nosocomial infection and hospital antibiotic consumption were investigated. Restriction of levofloxacin use was implemented to control the incidence of fluoroquinolone-resistant E coli in the hospital. Methods The study was conducted from January 2004 to December 2010. Antimicrobial agent consumption was obtained from the pharmacy computer system and presented as the defined daily doses per 1000 patient-days every 6 months. The incidence of fluoroquinolone-resistant E coli isolates causing nosocomial infections was obtained from the Department of Infection Control every 6 months. An antimicrobial stewardship program, restricting levofloxacain use, was implemented in July 2007. Results The incidence of fluoroquinolone-resistant E coli causing nosocomial infections was significantly correlated with fluoroquinolone usage (p?=?0.005), but not with the use of third- or fourth-generation cephalosporins, piperacillin-tazobactam, or carbapenems. Parenteral (p?=?0.002), oral (p?=?0.018), and total levofloxacin (p?=?0.001) use were significantly correlated with the extent of fluoroquinolone resistance. With a reduction of levofloxacin use, a decrease of the incidence of fluoroquinolone resistance in E coli isolates was observed. Conclusion There is a significant correlation between levofloxacin use and the incidence of nosocomial fluoroquinolone-resistant E coli isolates. The incidence of fluoroquinolone-resistant E coli could be reduced by limiting levofloxacin consumption. ? 2011
dc.identifier.doi10.1016/j.jmii.2011.12.019
dc.identifier.issn1684-1182
dc.identifier.pmid22560475
dc.identifier.scopus2-s2.0-84860544846
dc.identifier.urihttps://scholars.lib.ntu.edu.tw/handle/123456789/528277
dc.relation.ispartofJournal of Microbiology, Immunology and Infection
dc.relation.journalissue3
dc.relation.journalvolume49
dc.relation.pages424-429
dc.subject.classification[SDGs]SDG3
dc.subject.othercefepime; cefoperazone; cefotaxime; cefpirome; ceftazidime; ceftriaxone; ciprofloxacin; ertapenem; flomoxef; imipenem; levofloxacin; meropenem; moxifloxacin; piperacillin plus tazobactam; antiinfective agent; carbapenem derivative; cephalosporin derivative; levofloxacin; penicillanic acid; piperacillin; piperacillin, tazobactam drug combination; antibiotic sensitivity; Article; bacterium isolation; controlled study; disease association; drug use; Escherichia coli; hospital infection; human; incidence; nonhuman; analogs and derivatives; cross infection; drug effects; Escherichia coli; Escherichia coli Infections; isolation and purification; microbial sensitivity test; microbiology; multidrug resistance; Anti-Bacterial Agents; Carbapenems; Cephalosporins; Cross Infection; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Humans; Levofloxacin; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin
dc.titleCorrelation between levofloxacin consumption and the incidence of nosocomial infections due to fluoroquinolone-resistant Escherichia colien_US
dc.typejournal articleen
dspace.entity.typePublication

Files